目的 探討降糖通脈膠囊聯(lián)合利拉魯肽注射液對(duì)2型糖尿病的治療效果。方法 選取2022年7月—2023年7月聯(lián)勤保障部隊(duì)第九八七醫(yī)院收治的2型糖尿病患者98例，根據(jù)隨機(jī)數(shù)表法分為對(duì)照組（49例）和治療組（49例）。對(duì)照組患者給予利拉魯肽注射液，起始劑量0.6 mg/d，若血糖控制效果不理想則適當(dāng)增加劑量，最大不超過1.8 mg/d。治療組患者在對(duì)照組基礎(chǔ)上口服降糖通脈膠囊，3粒/次，3次/d。兩組患者均治療12周。觀察兩組患者臨床療效，比較治療前后兩組患者中醫(yī)癥狀積分，及餐后2 h血糖（2 h PBG）、空腹血糖、糖化血紅蛋白（HbA1c）、胰島素抵抗指數(shù)（HOMA-IR）水平。結(jié)果 治療后，治療組總有效率為95.92%，比對(duì)照組的83.67%明顯升高（P＜0.05）。治療后，兩組倦怠乏力、口渴喜飲、氣短懶言、多食易饑評(píng)分均明顯降低（P＜0.05），且治療組的各項(xiàng)評(píng)分均低于對(duì)照組（P＜0.05）。治療后，兩組餐后2 h血糖（2 h PPG）、空腹血糖、糖化血紅蛋白（HbA1c）、胰島素抵抗指數(shù)（HOMA-IR）水平均明顯降低（P＜0.05），且治療組的各項(xiàng)血糖指標(biāo)均低于對(duì)照組（P＜0.05）。結(jié)論 在利拉魯肽注射液的基礎(chǔ)上聯(lián)用降糖通脈膠囊治療2型糖尿病療效較為理想，能有效改善患者的中醫(yī)癥狀、控制體內(nèi)血糖水平，降低胰島素抵抗。

Objective To investigate the therapeutic effect of Jiangtang Tongmai Capsules combined with lilalutide in treatment of type 2 diabetes. Methods Patients (98 cases) with type 2 diabetes in the Joint Logistics Support Force 987th Hospital from July 2022 to July 2023 were divided into control (49 cases) and treatment (49 cases) group according to the random number table method. Patients in control group were administered with Liraglutide Injection, the initial dose was 0.6 mg/d, and if the effect of blood glucose control was not ideal, the dose should be increased appropriately, and the maximum was not more than 1.8 mg/d. Patients in the treatment group were po administered with Jiangtang Tongmai Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluations were evaluated, the TCM symptom scores, and the levels of 2 h PBG, fasting blood glucose, HbA1c and HOMA-IR in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 95.92%, which was significantly higher than that of the control group (83.67%, P < 0.05). After treatment, the scores of fatigue, thirst and drinking, shortness of breath and lazy talk, overeating and hunger were significantly decreased in two groups (P < 0.05), and the scores in the treatment group were lower than those in the control group (P < 0.05). After treatment, the levels of 2 h postprandial blood glucose (2 h PBG), fasting blood glucose, glycosylated hemoglobin (HbA1c) and insulin resistance index (HOMA-IR) were significantly decreased in two groups, and the blood glucose indexes in the treatment group were lower than those in the control group (P < 0.05). Conclusion On the basis of Liraglutide Injection, Jiangtang Tongmai Capsules is effective in the treatment of type 2 diabetes, which can effectively improve the symptoms of traditional Chinese medicine, control the level of blood glucose and reduce insulin resistance.

R977

陜西省科技計(jì)劃項(xiàng)目（2020SF-122）